Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting
Manzoor B, Huntington S, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting. Blood 2023, 142: 5085. DOI: 10.1182/blood-2023-177939.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaPost-index periodU.S. Medicare beneficiariesBTK inhibitorsHealth care costsMedicare beneficiariesTreatment periodIndex dateMonth 13Months 0Prescription coverageLymphocytic leukemiaHealthcare costsCare costsMonths post-index periodDiagnosis of CLLMonthly health care costsMonthly costCause total costsFixed-duration treatmentPre-index periodPrior CLL treatmentTreatment-free remissionBCL-2 inhibitor venetoclaxFront-line setting